Risk prediction of iron deficiency for plasmapheresis donors in China : Development and validation of a prediction model
Vox Sanguinis · 2024
DOI: 10.1111/vox.13572 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vox Sanguinis, 2024. Verfasst von Guanglin Xiao und 14 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, China. Hauptthemen laut MEDLINE: Iron Deficiencies, Anemia, Iron-Deficiency. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: CAMS Innovation Fund for Medical Sciences (CIFMS).
Abstract (Originalsprache)
Background and Objectives The present study aims to evaluate the iron stores in plasmapheresis donors and develop and validate an iron deficiency (ID) risk prediction model for plasmapheresis donors with potential or existing ID. Materials and Methods We assessed plasmapheresis donors' serum ferritin (SF) and haemoglobin (Hb) levels. The candidate factors showing significant differences in the multivariate logistic regression analysis were used to establish a risk prediction scoring system. The participants were divided into a training cohort and an internal validation cohort in a 7:3 ratio. Additional plasmapheresis donors from a different station were recruited for external validation.
Results
The SF levels in both male and female donors in the high‐frequency group were significantly lower than those of new donors (male: p < 0.001; female: p = 0.008). The prevalence of ID in female regular donors with a high frequency was significantly higher than that in new donors (33.1% vs. 24.6%; odds ratio = 1.209 [95% CI: 1.035–1.412]). Donation frequency, age, Hb, body mass index and being pre‐menopausal were identified as independent risk factors for ID ( p < 0.05). The developed model exhibited good discrimination ability (area under the receiver operating characteristic curve >0.7) and calibration ( p > 0.05) in development, internal validation cohorts and external validation cohorts.
Conclusion
A higher donation frequency has been associated with reduced SF levels and an increased risk of ID in women. The developed ID risk prediction model demonstrates moderate discriminative power and good model fitting, suggesting its potential clinical utility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, China.
- Nanyue Biopharmaceutical Corporation Ltd, Hengyang, Hunan, China.
- Sichuan Yuanda Shuyang Pharmaceutical Company Limited, Chengdu, Sichuan, China.
- Hualan Biological Engineering Inc, Xinxiang, Henan, China.
- Beijing Tiantan Biological Products Company Limited, Beijing, China.
- Linwu Plasmapheresis Station, Nanyue Biopharming Corporation Ltd, Hengyang, Hunan, China.
ORCID-Profile: Guanglin Xiao, Peizhe Zhao, Ya Wang
Förderung
- CAMS Innovation Fund for Medical Sciences (CIFMS)
Zitieren
APA
Xiao, G., Li, C., Chen, Y., Zhao, P., Li, W., Xiao, H., Yang, Y., Zhang, Y., Zhou, R., Liu, A., Liu, L., Du, L., Xiang, Q., Yang, J., & Wang, Y. (2024). Risk prediction of iron deficiency for plasmapheresis donors in China : Development and validation of a prediction model. Vox Sanguinis. https://doi.org/10.1111/vox.13572
Vancouver
Xiao G, Li C, Chen Y, Zhao P, Li W, Xiao H, et al. Risk prediction of iron deficiency for plasmapheresis donors in China : Development and validation of a prediction model. Vox Sanguinis. 2024. doi:10.1111/vox.13572
BibTeX
@article{Xiao2024,
author = {Xiao, Guanglin and Li, Changqing and Chen, Yongjun and Zhao, Peizhe and Li, Wan and Xiao, Hanzu and Yang, Yating and Zhang, Yu and Zhou, Rong and Liu, Aying and Liu, Lili and Du, Linzhi and Xiang, Qian and Yang, Jing and Wang, Ya},
title = {Risk prediction of iron deficiency for plasmapheresis donors in China : Development and validation of a prediction model},
journal = {Vox Sanguinis},
year = {2024},
doi = {10.1111/vox.13572}
}
EUVIMED